Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Targeting RAS signalling pathways in cancer therapy.

Downward J.

Nat Rev Cancer. 2003 Jan;3(1):11-22. Review.

PMID:
12509763
2.

Targeting new anticancer drugs within signalling pathways regulated by the Ras GTPase superfamily (Review).

Ramírez De Molina A, Rodríguez-González A, Lacal JC.

Int J Oncol. 2001 Jul;19(1):5-17. Review.

PMID:
11408916
3.

RAS: target for cancer therapy.

Saxena N, Lahiri SS, Hambarde S, Tripathi RP.

Cancer Invest. 2008 Nov;26(9):948-55. doi: 10.1080/07357900802087275. Review.

PMID:
18798058
4.

New druggable targets in the Ras pathway?

Matallanas D, Crespo P.

Curr Opin Mol Ther. 2010 Dec;12(6):674-83. Review.

PMID:
21154159
5.

Biomarkers downstream of RAS: a search for robust transcriptional targets.

Györffy B, Schäfer R.

Curr Cancer Drug Targets. 2010 Dec;10(8):858-68. Review.

PMID:
20718707
6.

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF.

Curr Cancer Drug Targets. 2008 May;8(3):187-98. Review.

PMID:
18473732
7.

[Progress in the study of antitumor drug targeting on the Ras signaling pathway].

Zhu YJ, Jiang FC.

Yao Xue Xue Bao. 2009 Jan;44(1):1-10. Review. Chinese.

PMID:
19350814
8.

Blocking oncogenic Ras signaling for cancer therapy.

Adjei AA.

J Natl Cancer Inst. 2001 Jul 18;93(14):1062-74. Review.

PMID:
11459867
9.

Ras-induced cellular events (review).

Ayllón V, Rebollo A.

Mol Membr Biol. 2000 Apr-Jun;17(2):65-73. Review.

PMID:
10989457
10.

Key cancer cell signal transduction pathways as therapeutic targets.

Bianco R, Melisi D, Ciardiello F, Tortora G.

Eur J Cancer. 2006 Feb;42(3):290-4. Epub 2006 Jan 11. Review.

PMID:
16376541
11.
12.

Tailoring Ras-pathway--inhibitor combinations for cancer therapy.

Blum R, Kloog Y.

Drug Resist Updat. 2005 Dec;8(6):369-80. Epub 2005 Dec 13. Review.

PMID:
16356760
13.

Targeting RAS signaling pathways in juvenile myelomonocytic leukemia.

Flotho C, Kratz C, Niemeyer CM.

Curr Drug Targets. 2007 Jun;8(6):715-25. Review.

PMID:
17584027
14.

Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs.

Sebti SM, Hamilton AD.

Biochem Soc Trans. 1996 Aug;24(3):692-9. Review. No abstract available.

PMID:
8878828
15.

Cancer targets in the Ras pathway.

Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F.

Cold Spring Harb Symp Quant Biol. 2005;70:461-7. Review.

PMID:
16869784
16.

[Oncogenes and tumor suppressor genes in the signal transduction pathways of growth factors].

Buday L.

Orv Hetil. 1994 Nov 20;135(47):2579-84. Review. Hungarian.

PMID:
7824256
17.

Ras family signaling: therapeutic targeting.

Cox AD, Der CJ.

Cancer Biol Ther. 2002 Nov-Dec;1(6):599-606. Review.

PMID:
12642680
18.

STAT proteins as novel targets for cancer drug discovery.

Turkson J.

Expert Opin Ther Targets. 2004 Oct;8(5):409-22. Review.

PMID:
15469392
19.

Re: Blocking oncogenic Ras signaling for cancer therapy.

Canevari S, Biocca S, Figini M.

J Natl Cancer Inst. 2002 Jul 3;94(13):1031-2; author reply 1032. No abstract available.

PMID:
12096090
20.

Farnesyltransferase inhibitor as anticancer agent.

Agrawal AG, Somani RR.

Mini Rev Med Chem. 2009 Jun;9(6):638-52. Review.

PMID:
19519490

Supplemental Content

Support Center